Stem Cell Transplantation for Patients With Hematologic Malignancies
Acute Lymphoblastic Leukemias, Acute Myelocytic Leukemia, Chronic Myeloid Leukemia
About this trial
This is an interventional treatment trial for Acute Lymphoblastic Leukemias focused on measuring High risk hematologic malignancies, Allogeneic stem cell transplant, Matched unrelated donor transplantation, Unmanipulated stem cell graft, Bone marrow transplantation
Eligibility Criteria
Inclusion Criteria: All patients lacking an HLA identical sibling for whom an unrelated donor matched at 6/6 HLA loci is formally requested within about 3 months of search initiation Age greater than or equal to 24 months, but less than 21 years for new patients. Diagnosis of one of the following high risk hematological malignancies: Acute lymphoblastic leukemia (in second or subsequent remission or high risk in first remission) Acute myeloid leukemia (in relapse or remission) Secondary AML/MDS Chronic myeloid leukemia Juvenile myelomonocytic leukemia Myelodysplastic syndrome Paroxysmal nocturnal hemoglobinuria Non-Hodgkin's lymphoma (in second or subsequent remission) Exclusion Criteria: Patients with symptomatic cardiac disease, or evidence of significant cardiac disease by echocardiogram, or cardiac shortening fraction below 25% Patients with renal creatinine clearance < 40ml/min/1.73m^2 Patients with FVC < 40% predicted or pulse oximetry less than or equal to 92% on room air if unable to perform pulmonary function tests Patients with direct bilirubin > 3 mg/dl Patients with SGPT > 500 U/L Patients with a Karnofsky or Lansky performance score < 70 Patients who have received a previous allogeneic stem cell transplant Patients with a known allergy to rabbit or murine products Patients with isolated extramedullary leukemic relapse, including isolated CNS or testicular recurrence
Sites / Locations
- St. Jude Children's Research Hospital
Arms of the Study
Arm 1
Other
1